RJM has served on advisory panels and speakers bureau for Sanofi and Novo Nordisk (related to once-weekly GLP1RAs and fixed ratio combination therapies); has received research support from the European Union, Medical Research Council, Chief Scientists Office, Diabetes UK, and the Juvenile Diabetes Research Foundation; and reports clinical trial fees paid to his institution from Novo Nordisk, Lilly, Pfizer, and Boehringer Ingelheim all related broadly to diabetes research but unrelated to once-weekly insulins. RJM is a non-executive member of NHS Tayside Health Board.